Compare Oracle Corporation (ORCL) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oracle Corporation vs TransMedics Group Inc — how do they compare? Oracle Corporation trades at $141.34 (market cap $411.34B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: Oracle Corporation is far larger — about 150.1× TransMedics Group Inc's market cap, and Oracle Corporation pays a 1.47% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oracle Corporation for 72 Days and TransMedics Group Inc for 24 Days on average.
| ORCL | TMDX | |
|---|---|---|
Market Cap | $411.34B | $2.74B |
Volume | 41,276,815 | 949,331 |
Sector | Technology | Health |
52-Week High | $313.00 | $150.42 |
52-Week Low | $114.99 | $61.99 |
Typical Hold Time | 72 Days | 24 Days |
Enterprise Value | $535.15B | $3.13B |
Dividend Yield | 1.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Oracle (ORCL) trades at $143.56, down 0.83% amid a bearish technical signal, though recent earnings consistently beat expectations with Q2 2026 EPS of $1.92 versus $1.74 expected. The company shows strong fundamentals with 2025 revenue of $57.40B and net income margin of 26.36%, while analyst consensus remains bullish with a $236.52 price target. News highlights AI cloud growth of 120% in Q1 2026 but also layoffs and market concerns over AI spending cycles.
The outlook is mixed: robust AI-driven revenue growth and high profitability support upside, but technical weakness and macroeconomic risks like Fed policy pose near-term headwinds. Investors face opportunity from AI demand against volatility from high debt and competitive pressures.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
